Updates

Announcements

Top line results of Lupuzor™ Pivotal Phase III Trial

Apr 17, 2018

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces the results of its pivotal Phase III trial of Lupuzor™, its lead programme for the potential breakthrough compound for Lupus. Key highlights: Lupuzor™ demonstrated a superior response rate over placebo* (52.5% vs 44.6% “responders”**) in the primary analysis on the Full Analysis Set of…
Appointment of Joint Broker

Mar 28, 2018

ImmuPharma PLC (AIM: IMM.L), the specialist drug discovery and development company, is pleased to announce that it has with immediate effect appointed Bryan, Garnier & Co. Limited as its joint corporate broker to act alongside Northland Capital Partners who remain the Company’s Nominated Adviser and joint corporate broker. Tim McCarthy, Chairman of Immupharma, commented: “We…
Lupuzor™ ‘database lock’ confirmed for 6 April 2018

Mar 23, 2018

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company announces that it has been informed by Simbec-Orion, the contract research organisation conducting our Lupuzor™ pivotal Phase III trial study, that ‘database lock’ is expected on 6 April 2018 with top line results announced by mid-April 2018. Lupuzor™ is the Company’s lead programme for the…
London Investor Evening – Monday 26 February 2018 @ 6pm

Feb 15, 2018

ImmuPharma PLC (LSE: IMM), specialist drug discovery and development company, is pleased to announce that Tim McCarthy, Chairman, will be presenting at an investor evening hosted by Turner Pope Investments (TPI) Ltd. TPI acted as agent in the recent successful £10 million fundraise by ImmuPharma. The event will be held on Monday 26th February 2018…
Holding in Company

Feb 8, 2018

ImmuPharma PLC (LSE: IMM), the specialist drug discovery and development company, announces that on 8 February 2018 it received notification that Alto Invest no longer holds a notifiable interest in the Company. This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.
Notification of Major Interest – Lanstead Increases Holding to over 5%

Feb 5, 2018

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, has received notification that Lanstead Capital LP (“Lanstead”) has confirmed an increase in its holding in ImmuPharma. Lanstead now holds 6,985,893 Ordinary shares of 10p each in the Com-pany, representing 5.01% of ImmuPharma’s issued share capital of 139,467,430 Ordinary shares with voting rights. This announcement…
Successful Placing to Raise £10 Million

Jan 24, 2018

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to announce that, in response to institutional demand, it has completed a fundraise totalling £10 million (before expenses) via a placing of 6,944,445 new ordinary shares of 10p each in the Company (“Ordinary Shares”) at a price of 144p per share (the “Placing…
Completion of Lupuzor™ Pivotal Phase III Study and Initiation of Follow Up Study

Jan 18, 2018

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to confirm that the ongoing 52-week, randomised, double-blinded, Phase III clinical trial of Lupuzor™, its lead programme for the potential breakthrough compound for Lupus, is now complete, following the last patient having attended their final assessment. Final patient data from the trial are…
Update on Lupuzor™ Pivotal Phase III Study

Nov 28, 2017

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to provide an update of its pivotal 52-week, randomised, double-blinded, Phase III clinical trial of Lupuzor™, its lead programme for the potential breakthrough compound for Lupus, the life threatening auto-immune disease. Study summary as at 1st November 2017 • 200 patients successfully recruited…
ImmuPharma PLC (“ImmuPharma” or the “Company”) Holding(s) in Company

Nov 28, 2017

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, has received notification that Alto Invest now holds 5,242,536 ordinary shares of 10p each in the Company, representing 3.96% of the Company’s issued share capital with voting rights. This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.
Successful Completion of Lanstead Sharing Agreement

Nov 6, 2017

ImmuPharma plc (LSE: IMM), the specialist drug discovery and development company, wishes to announce the completion of the Sharing Agreement entered into with Lanstead Capital L.P. (‘Lanstead’) in February 2016 (“Sharing Agreement”). As announced on 5 February 2016, Lanstead subscribed for £4.4 million of new ordinary shares in ImmuPharma, with both parties also entering into…
Interim Results Announcement for the six months ended 30 June 2017

Sep 27, 2017

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce its interim results for the six months ended 30 June 2017 (the “Period”). Key Highlights Lupuzor™: is the Company’s lead program for the potential breakthrough compound for Lupus a potential life threatening auto-immune disease • Total 11…
ImmuPharma initiates preparation of Lupuzor’s™ regulatory submissions

Sep 27, 2017

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to confirm a further update on Lupuzor™ its lead programme for the potential breakthrough compound for Lupus, the life threatening auto-immune disease. On 21 September 2017 ImmuPharma announced that that all patients in the Company’s pivotal Phase III Lupuzor™ study had passed the…
Update on Lupuzor™ Pivotal Phase III Study

Sep 21, 2017

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to provide an update of its pivotal 52-week, randomised, double-blinded, Phase III clinical trial of Lupuzor™, its lead programme for the potential breakthrough compound for Lupus, the life threatening auto-immune disease. Study summary as at 15th September 2017 • 200 patients successfully recruited…
2017 Annual General Meeting – All Resolutions Passed

Jul 3, 2017

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, held its AGM earlier today and is pleased to announce that all resolutions were duly passed.
Annual General Meeting and Investor Presentation

Jun 30, 2017

Update on Lupuzor™ Pivotal Phase III Study A video of the presentation will be available to view on the Company’s website from Monday 3 July 2017 at www.immupharma.co.uk/events/2017 Download the June 2017 IMM presentation
Notice of Annual General Meeting on 30 June 2017 at 10.30am

Jun 7, 2017

Notice of Annual General Meeting on 30 June 2017 at 10.30am Investor presentation to follow at 11.30am Venue: Sky Light City, 50 Basinghall Sreet, London, EC2 ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company confirms that today the Annual Report and Accounts for the year ended 31 December 2016…
Final Results Announcement for the twelve months ended 31 December 2016

Jun 6, 2017

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce its final results for the twelve months ended 31 December 2016 (the “Period”). Key Highlights (including post Period review) Lupuzor™: is the Company’s lead program for the potential breakthrough compound for lupus a potential life threatening auto-immune…
Notification of full year results – 1st June 2017

May 24, 2017

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, confirms that it will be announcing its full year results for the year ended 31 December 2016 on Thursday 1 June 2017.
Update on Lupuzor™ Pivotal Phase III Study

May 18, 2017

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to provide an update of its pivotal 52-week, randomised, double-blinded, Phase III clinical trial of Lupuzor™, its lead programme for the potential breakthrough compound for Lupus, the life threatening auto-immune disease. Study Summary 200 patients successfully recruited and randomised (dosed) 7 Countries and…
Notification of Major Interest by Legal & General

Mar 21, 2017

ImmuPharma PLC (LSE:IMM) (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, announces that it has received notification by Legal & General Group Plc (“L&G”) confirming its holding in ImmuPharma of 4,446,545 million Ordinary Shares in the capital of the Company, representing 3.35% of ImmuPharma’s total voting rights figure of 132,522,985 Ordinary Shares.…

2025 (24)

2024 (19)

2023 (25)

2022 (27)

2021 (21)

2020 (40)

2019 (19)

2018 (22)

2017 (17)

2016 (25)

2015 (17)

2014 (12)

2011 (2)

Lisa Baderoon

Non-Executive Director and Head of Investor Relations

Lisa has spent over 25 years working within the City of London being involved with a diverse portfolio of clients from a variety of sectors but with a leaning towards emerging, high growth businesses advising both private and public companies on their financial and corporate strategies aligned to stakeholder and investor interests, as well as a strong acumen in media communication. During this time, she has been involved in a multitude of client transactions spanning private fund raisings, Initial Public Offerings (IPOs), secondary high profile capital raisings and mergers and acquisitions both in the UK and internationally.

Lisa had a successful career spanning 20 years as a Partner at Buchanan Communications, one of the leading City financial public relations agencies. As one of the youngest Board members, she was involved in the successful five-year earnout, as part of Buchanan being acquired by the FTSE 100 rated WPP Plc in 1997.

Lisa founded Just B Communications Ltd in 2012 with the key objective of working with a more select number of clients and providing a greater degree of bespoke advisory services thus becoming more integral to the day to day corporate and strategic development for these businesses. She has successfully advised a number of public and private companies, at Board level, on corporate strategy, stakeholder and investor communications, capital raisings, dual listings, licensing and M&A. Media profiling, where required, has also played an important role in advisory activities.

Lisa was appointed Head of Investor Relations at ImmuPharma in 2012 and most recently appointed as a Non-Executive Director in July 2021.

Ketan Patel

Independent Non-Executive Director

Ketan is an experienced investment professional who brings extensive expertise in financial markets, with a particular focus on the UK healthcare and life science sectors. He has been a long-term investor in UK markets, working as both an analyst and Fund Manager, managing institutional, retail, and charity mandates. Ketan began his career at JP Morgan before moving to Insight Investment, where he served as a global Pharmaceutical and Healthcare analyst. He then spent over 20 years at EdenTree Investment Management, where he was responsible for UK equity and global equity income strategies, consistently delivering upper-quartile performance.

Ketan combines rigorous fundamental analysis with risk-focused investment strategies. He is also a published thought leader on sustainability and investment themes. Ketan is a CFA Charterholder and holds an MSc in Economic History from the London School of Economics, an MSc in Geography from King’s College London, and a BA (Hons) in History and Geography from Queen Mary University, London.

Dr Laurence Reilly MBA

Senior Independent Non-Executive Director

Dr Laurence Reilly has been appointed as Senior independent Non-Executive Director and Chair of the Audit Committee. Dr Reilly brings extensive experience in managing late-stage clinical programs through to approval, in addition to commercial and business development experience.

He is currently Vice President of Research & Investments, working with Royalty Pharma, a New York based life science investment company focussing on acquisition of biopharmaceutical royalties and funding of innovation across the biopharmaceutical industry.

Through his consulting practice (Acumen Life Science Investment Consulting) Dr Reilly has provided strategic consulting and due-diligence services to biotech companies, life science venture capital and private equity clients. He also served as Chief Medical Officer for Cellectar Biosciences, New Jersey, a late-stage oncology biotech company. Prior to founding his consulting practice, Dr Reilly served as Chief Scientific Officer and Vice President at Avillion, a drug development company focused on the co-development and financing of drug candidates, where he was responsible for clinical and strategic oversight of co-development programs and partnering with both large pharma and biotech, including Pfizer, Merck KGaA and AstraZeneca. Dr. Reilly previously served as a Clinician – Clinical Development & Medical Oversight at Pfizer and at Lundbeck as Medical & Scientific Advisor.

Dr Reilly earned his medical degree from the University of Liverpool Medical School, U.K., and practiced as Neurosurgery Resident at Queen Elizabeth University Hospital in Birmingham. Dr Reilly also holds a Masters Degree in Law from De Montfort University, U.K.

Dr Tim Franklin PhD, MBA

Chief Operating Officer

Tim has 30 years’ experience in the biopharmaceutical industry. He worked in clinical research, sales & marketing, and global strategic marketing for Warner Lambert, Wellcome and SmithKline Beecham. He later moved to the capital markets where he became a top-ranked pharmaceuticals analyst at Dresdner Kleinwort investment bank. He applied his experience to stock selection at hedge funds and advised several small biotechnology companies on corporate and commercial strategy and access to capital. He holds a BSc in Medicinal Chemistry and a PhD in Pharmacology from Loughborough University and an MBA from Warwick Business School.

Dr Laura Mauran-Ambrosino Ph.D.

Head of R&D

Born in Montpellier, France, Dr Mauran- Ambrosino obtained her PhD in Chemistry at the Université de Bordeaux as a CIFRE fellow in co-supervision by Dr Goudreau.

She then conducted postdoctoral studies at the “Centre Hospitalier Universitaire” Pellegrin in cell biology. In 2018, she joined Ureka and established the biology department and the analytical chemistry department and in 2021, she became Chief Scientific Officer of Ureka Pharma. Dr Mauran-Ambrosino was a key contributor to the development of BioGlucagon, and BioAMB.

Ashley Clarke ACA

Chief Financial Officer & Company Secretary

Ashley brings over a decade of experience in the financial sector. She began her career at a Big Four accounting firm and later advanced her professional expertise by earning her ACA qualification with a respected local firm.

Her professional journey is rooted in auditing, where she developed expertise working with a diverse portfolio of audit and non-audit clients across various industries. Ashley’s experience spans from supporting SMEs to managing large international group consolidations, giving her a comprehensive understanding of financial management across different business scales.

Ashley has been closely involved with the company’s accounts for several years via outsourced accountants, providing her with deep familiarity with its operations. Now, as Group CFO and Company Secretary, she is poised to leverage her extensive knowledge to drive strategic financial growth and ensure robust fiscal management.

Dr Sébastien R. Goudreau Ph.D.

Chief Scientific Officer

Born in Sherbrooke, Québec, Canada, Dr Goudreau obtained his PhD in Chemistry at the Université of Montréal as a NSERC fellow before moving to Switzerland to conduct postdoctoral studies at the ETH Zürich as an FRQNT fellow. He then moved back to Canada for one year where he co-founded FindMolecule inc. and worked for the pharma industry.

In 2014 he joined ImmuPharma as research director and established the research laboratories of Ureka in Bordeaux. After the merger of ELRO with Ureka in 2019, Dr Goudreau became Chief Scientific Officer of Ureka Pharma and in 2021, he became Chief Executive Officer of ImmuPharma Biotech. Notably, Dr Goudreau and his team are credited for the discovery and development of, among others, URK 614, BioGlucagon, and BioAMB.

Tim McCarthy FCCA, MBA

Chief Executive Officer

Tim has 40 years’ international senior level business experience in high growth biotech, healthcare and technology companies. He is also Chairman of Incanthera plc. Tim was formerly Chairman of 4basebio plc and CEO and CFO of a number of UK public listed and private companies including, Alizyme plc and Peptide Therapeutics Group plc, and has a core understanding of AIM and its regulatory processes. Co-founding a number of healthcare and biotechnology companies, he has helped raise substantial amounts of equity capital and also advised and worked at Board level for a diverse range of companies internationally, in areas such as business strategy, mergers & acquisitions, due diligence and licensing.

Announcements

Top line results of Lupuzor™ Pivotal Phase III Trial

Appointment of Joint Broker

Lupuzor™ ‘database lock’ confirmed for 6 April 2018

London Investor Evening – Monday 26 February 2018 @ 6pm

Holding in Company

Notification of Major Interest – Lanstead Increases Holding to over 5%

Successful Placing to Raise £10 Million

Completion of Lupuzor™ Pivotal Phase III Study and Initiation of Follow Up Study

Update on Lupuzor™ Pivotal Phase III Study

ImmuPharma PLC (“ImmuPharma” or the “Company”) Holding(s) in Company

Successful Completion of Lanstead Sharing Agreement

Interim Results Announcement for the six months ended 30 June 2017

ImmuPharma initiates preparation of Lupuzor’s™ regulatory submissions

Update on Lupuzor™ Pivotal Phase III Study

2017 Annual General Meeting – All Resolutions Passed

Annual General Meeting and Investor Presentation

Notice of Annual General Meeting on 30 June 2017 at 10.30am

Final Results Announcement for the twelve months ended 31 December 2016

Notification of full year results – 1st June 2017

Update on Lupuzor™ Pivotal Phase III Study

Notification of Major Interest by Legal & General

2025 (24)

2024 (19)

2023 (25)

2022 (27)

2021 (21)

2020 (40)

2019 (19)

2018 (22)

2017 (17)

2016 (25)

2015 (17)

2014 (12)

2013 (7)

2012 (8)

2011 (2)